Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages 145-153

  Bourhis, Jean ^a   Sire, Christian ^b   Graff, Pierre ^c   Grégoire, Vincent ^d   Maingon, Philippe ^e   Calais, Gilles ^f   Gery, Bernard ^g   Martin, Laurent ^h   Alfonsi, Marc ⁱ   Desprez, Patrick ^j   Pignon, Thierry ^k   Bardet, Etienne ^l   Rives, Michel ^m   Geoffrois, Lionel ^c   Daly Schveitzer, Nicolas ^m   Sen, Sok ⁿ   Tuchais, Claude ^o   Dupuis, Olivier ^p   Guerif, Stéphane ^q   Lapeyre, Michel ^r   Favrel, Véronique ^s   Hamoir, Marc ^d   Lusinchi, Antoine ^a   Temam, Stéphane ^a   Pinna, Antonella ^a   Tao, Yun Gan ^a   Blanchard, Pierre ^a   Aupérin, Anne ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre Hospitalier de Lorient   (France)

^c CENTRE ALEXIS VAUTRIN   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e Centre F Leclerc   (France)

^f CHU BRETONNEAU   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h Centre G Le Conquérant   (France)

ⁱ INSTITUT SAINTE CATHERINE   (France)

^j Clinique d'Oncologie   (France)

^k TIMONE HOSPITAL   (France)

^l CENTRE RENÉ GAUDUCHEAU   (France)

^m INSTITUT CLAUDIUS REGAUD   (France)

ⁿ CENTRE HENRI BECQUEREL   (France)

^o Centre Claude Papin   (France)

^p CENTRE JEAN BERNARD   (France)

^q Centre Hospitalo Universitaire de Poitier   (France)

^r CENTRE JEAN PERRIN   (France)

^s CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL;

ACCELERATION; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OROPHARYNX CARCINOMA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADULT; AGED; CARCINOMA; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SAFETY; TREATMENT OUTCOME;

EID: 84856485375     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70346-1     Document Type: Article

References (26)

1. Pignon JP, Bourhis J, Domenge C, Designé L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955. on behalf of the MACH-NC Collaborative Group.
2. Pignon JP, le Maitre A, Maillard E, Bourhis J Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
3. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715.
4. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704.
5. Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010, 21:1515-1522.
6. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101:498-506.
7. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
8. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005, 23:1125-1135.
9. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006, 64:983-994.
10. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
11. Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 2010, 11:66-74.
12. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radio-chemoradiotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003, 55:93-98.
13. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck 2005, 27:843-850.
14. Tao Y, Rezaï K, Brain E, et al. A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous-cell carcinoma. Radiother Oncol 2011, 98:42-47.
15. Choe KS, Salama JK, Stenson KM, et al. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol 2010, 97:318-321.
16. Horiot JC, LeFur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25:231-241.
17. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
18. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Proc Am J Clin Oncol 2011, 29. abstr 5500.
19. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated of accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-854. on behalf of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group.
20. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006, 24:2873-2878.
21. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362:933-940.
22. Proschan MA, Follmann DA Multiple comparisons with control in a single experiment versus separate experiments: why do we feel differently?. Am Stat 1995, 49:144-149.
23. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1992-1998.
24. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
25. Lefebvre JL, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. Proc Am J Clin Oncol 2011, 29. abstr 5501.
26. Suit H, DeLaney T, Goldberg S, et al. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol 2010, 95:3-22.